Astra Zeneca will commence a new study called EUCLID of Brilinta/Brilique(ticagrelor) to compare twice daily dosing of Brilinta/Brilique with once...
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.
The U.S. Justice Department's civil division is to investigate the PLATO study related to Brilinta/Brilique (ticagrelor) from AstraZeneca, requesting documents...
Brilique/Brilinta (ticagrelor) from AstraZeneca has been reviewed by the German Institute for Quality and Efficiency in Health Care (IQWiG) )...
AstraZeneca announced that the PEGASUS-TIMI 54 study, which assessed Brilinta (ticagrelor) plus low-dose aspirin for the secondary prevention of atherothrombotic...
AstraZeneca and The Medicines Company have announced a global collaboration for their acute ischaemic heart disease compounds. The first part...
AstraZeneca announced top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared...
AstraZeneca has announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial...
The FDA has accepted a supplemental new drug application (sNDA) and granted Priority Review for Brilinta (ticagrelor) tablets, from AstraZeneca,...
AstraZeneca announced top-line results from the EUCLID trial. Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic...